Tyrosine kinase inhibitorPhase 3 trialInvestigational
Capmatinib
How it works
Blocks the MET receptor on cancer cells, preventing them from growing and dividing.
Cancer types
Lung Cancer— MET exon 14 skipping mutation
Efficacy
In clinical trials, around 70% of MET exon 14 skipping mutation patients achieved an objective response, with median progression-free survival of approximately 9 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Capmatinib's Effectiveness in Lung Cancer Treatment | Lung Cancer | review | — | Source → |
| Capmatinib Efficacy in Lung Cancer Patients with METex14 Mutation | Lung Cancer | phase-2 | The overall response rate was 55.3% (95% CI 46.8%-63.6%). | Source → |
| Study Finds New Safety Signals for Cancer Treatment Capmatinib | Lung Cancer | observational | — | Source → |
| Combination Therapy Shows Promise in Lung Cancer Treatment | Lung Cancer | phase-2 | The estimated mean 6-month progression-free survival rate was 68.9% (high-MET group) and 50.9% (low-MET group). | Source → |
| Capmatinib Improves Symptoms and Quality of Life in Lung Cancer Patients | Lung Cancer | phase-2 | Median time to definitive deterioration in quality of life was 16.6 months in treatment-naive patients and 12.4 months in pre-treated patients. | Source → |
| Capmatinib May Help Reduce Inflammation in Blood Vessels | Lung Cancer | lab-study | — | Source → |
| Capmatinib Shows Promise in Treating Lung Cancer with MET Gene Mutation | Lung Cancer | phase-2 | The overall response rate was 50% for patients with MET GCN ≥ 10 or METex14. | Source → |
| Capmatinib's Budget Impact on Lung Cancer Treatment in the US | Lung Cancer | phase-3 | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.